Holen Sie sich die Stockscreener-App
23.35
0.99%
0.23
Handel nachbörslich:
23.38
0.03
+0.13%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer (PFE) Stock Gains Over 1% in Trading, Shows Mixed Longer-Term Performance - Daily Chhattisgarh News
Will Pfizer Walk Away From Arvinas After PROTAC Disappointment? - insights.citeline.com
Hartford HealthCare and Pfizer partner to tackle workplace migraines - WTNH.com
Arvinas (ARVN) and Pfizer Submit FDA Application for Breast Canc - GuruFocus
Pfizer, Arvinas seek FDA nod for breast cancer therapy (ARVN) - Seeking Alpha
Was Jim Cramer Right About Pfizer Inc. (PFE)? - Insider Monkey
Arvinas stock rises on FDA submission with Pfizer - Investing.com Australia
Arvinas and Pfizer seek FDA approval for breast cancer drug - Investing.com Australia
Arvinas and Pfizer seek FDA approval for breast cancer drug By Investing.com - Investing.com Nigeria
Arvinas (ARVN) and Pfizer Submit NDA for Breast Cancer Treatment - GuruFocus
Arvinas, Pfizer Submit New Drug Application for Vepdegestrant as Breast Cancer Treatment - marketscreener.com
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer - GlobeNewswire Inc.
Pfizer Secures Global Licensing Rights Outside China for 3SBio’s Cancer Therapy Targeting PD-1 and VEGF - geneonline.com
Pfizer (PFE) Stock Dips on NYSE, Continuing Recent Downward Trend Despite Strong All-Time Gains - Daily Chhattisgarh News
Pfizer (NYSE:PFE) Exceeds Sales Milestone With Cresemba In Asia Pacific And China - simplywall.st
Ex-Pfizer CEO looks to part with his condo near Central Park - Crain's New York Business
Joint Pain Injections Market to Witness Remarkable Growth with - openPR.com
Geriatric Medicines Market Is Booming So Rapidly 2025-2032 - openPR.com
Basilea to Receive $2.5 Million Milestone Payment from Pfizer for Cresemba Sales - marketscreener.com
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis - Yahoo Finance
Basilea Pharmaceutica Ltd, Announces Continued Strong Sales Performance of the Antifungal Cresemba® (isavuconazole) by Its License Partner Pfizer Inc - marketscreener.com
US appeals court sides with Moderna on COVID patent claims - Reuters
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (June 2025) - 24/7 Wall St.
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes - The Manila Times
Over The Counter Drugs Market Growth in Future Scope 2025-2032 | - openPR.com
Cardiovascular Drugs Market Growth Set to Surge Significantly - openPR.com
Zacks.com featured highlights StoneCo, Centene, CVS Health and Pfizer - Nasdaq
PFIZER INC : Bernstein reaffirms its Neutral rating - marketscreener.com
Pfizer: I Should Have Sold Earlier (Downgrade) (NYSE:PFE) - Seeking Alpha
Pfizer's R&D Optimization Delivers Great Results & Secure Dividends (NYSE:PFE) - Seeking Alpha
Pfizer Seeks Mass Tort Coordination of Phila. Depo-Provera Lawsuits - Law.com
Takeda, Pfizer's Adcetrix wins EU approval for hodgkin lymphoma - Seeking Alpha
Buy, Sell, Or Hold Pfizer Stock At $23? - Forbes
3 Low-Priced Dividend Stocks Paying Over 5% Right Now - 24/7 Wall St.
PFIZER INC : JP Morgan is Neutral - marketscreener.com
Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space - insights.citeline.com
Jim Cramer Says “We Can Own The Stock of Pfizer (PFE)” - MSN
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics - FinancialContent
ASCO: Pfizer’s Braftovi combo regimen cuts risk of death - The Pharma Letter
ASCO: Positive Phase III results for Arvinas and Pfizer's vepdegestrant - The Pharma Letter
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - BioSpace
Morgan Stanley, Walmart, Pfizer and more: Full list of over 150 American companies laying off employees in June - The Economic Times
Arvinas, Pfizer Report Breast Cancer Treatment Phase 3 Trial Results; Arvinas Shares Down Pre-Bell - marketscreener.com
Arvinas and Pfizer Announce Phase 3 Trial Results - TipRanks
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE) - Yahoo Finance
Pfizer’s Braftovi regimen shows promise in metastatic colorectal cancer - World Pharmaceutical Frontiers
A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising - BioPharma Dive
400 Women Are Suing Pfizer Over Birth Control Shot That Allegedly Gave Them Brain Tumors - futurism.com
Terrible News for Pfizer Stock Investors - Nasdaq
Pfizer-Arvinas breast cancer drug tops AstraZeneca’s in delaying progression - WTVB
Pfizer CEO: HHS claims of ‘concealed safety concerns’ on mRNA vaccines are ‘completely inaccurate’ - WAAY 31 News
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression - Reuters
Pfizer and Arvinas Plan FDA Submission for Breast Cancer Drug - GuruFocus
Pfizer, Arvinas report positive breast cancer drug trial - breakingthenews.net
Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2 - Seeking Alpha
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer - Pfizer
Arvinas And Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival For Patients With Esr1-Mutant, Er+/Her2- Advanced Breast Cancer - marketscreener.com
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progre - GuruFocus
1.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):